Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

被引：0
|
作者：
Hamadani, Mehdi
Graham, Christopher N.
Liao, Laura
Zhang, Katherine H.
Strat, Hannah
Ungar, David
Ai, Weiyun Z.
Chen, Lei
Carlo-Stella, Carmelo
机构：
[1] BMT & Cellular Therapy Program, Med Coll Wisconsin, Milwaukee, WI USA
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
[3] ADC Therapeut Inc, New Providence, NJ USA
[4] ADC Therapeut Amer Inc, Clin Dev, Murray Hill, NJ USA
[5] Univ Calif San Francisco, Div Hematol & Oncol, Dept Med, San Francisco, CA USA
[6] Humanitas Res Hosp, Rozzano, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19551
引用
收藏
页数：1
相关论文
共 50 条
  • [41] In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine
    Caimi, Paolo F.
    Hamadani, Mehdi
    Carlo-Stella, Carmelo
    Nickaeen, Masoud
    Jordie, Eric
    Utsey, Kiersten
    Knab, Tim
    Zammarchi, Francesca
    Cucchi, Danilo
    Pantano, Serafino
    Havenith, Karin
    Wang, Ying
    Boni, Joseph
    EJHAEM, 2024, 5 (01): : 76 - 83
  • [42] Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
    Saverno, Kimberly
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Gordon, Sarah
    Amoloja, Theresa
    Llorente, Mae
    Epperla, Narendranath
    Nastoupil, Loretta J.
    BLOOD, 2023, 142
  • [43] Preferences and Perceptions Regarding Treatment Decision-Making for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Yung, Mallory
    Schnell, Frederick
    Vukcevic, Mirko
    Kurukulasuriya, Nuwan C.
    BLOOD, 2021, 138 : 1928 - +
  • [44] Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Kurtz, David M.
    Hogan, Gregory
    Schultz, Andre
    Chabon, Jacob J.
    Alizadeh, Ash A.
    Havenith, Karin
    Samari, Sara
    Kopotsha, Tim
    Wang, Luqiang
    Qin, Yajuan
    Wang, Ying
    Pantano, Serafino
    BLOOD, 2023, 142
  • [45] Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy
    Di Rocco, Alice
    Di Rocco, Arianna
    Farcomeni, Alessio
    Petrucci, Luigi
    De Luca, Giulia
    Mazzon, Federico
    Martelli, Maurizio
    Foa, Robin
    BLOOD, 2019, 134
  • [46] Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany
    Buecklein, Veit L.
    Ayuk, Francis A.
    Holderried, Tobias A. W.
    Mai, Christine
    Kievit, Bradley
    Blisset, Rob
    Doble, Brett
    Reid, Geoff
    Reimeir, Laura
    Bruns, Caroline
    Vadgama, Sachin
    BLOOD, 2024, 144 : 5037 - 5038
  • [47] Discovery of plasma protein biomarkers associated with overall survival in R/R DLBCL patients treated with loncastuximab tesirine
    Vallania, Francesco
    Cheung, Victoria
    Tripathi, Anupriya
    Louie, Maggie
    Snyder, Thomas
    Lin, Jimmy
    Havenith, Karin
    Qin, Yajuan
    Pantano, Serafino
    Wuerthner, Jens
    van Berkel, Patrick H.
    CANCER RESEARCH, 2023, 83 (07)
  • [48] Epcoritamab versus standard of care in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) - a phase 3 study (EPCORE DLBCL-1)
    Hess, G.
    Thieblemont, C.
    Clausen, M. R.
    Lugtenburg, P.
    Balari, Sureda A.
    Zinzani, P. L.
    Wu, J.
    Finn, L.
    Vindelov, S. D.
    Fox, C. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 192 - 193
  • [49] Symptoms, Health-Related Quality of Life, and Tolerability of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma
    Spira, Alexander I.
    Chen, Lei
    Zhou, Xiaolei
    Gnanasakthy, Ari
    Wang, Luqiang
    Ungar, David
    Curiel, Rafael
    Radford, John A.
    Kahl, Brad S.
    BLOOD, 2020, 136
  • [50] Grading of Neurotoxicity in Patient with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study
    Maziarz, Richard T.
    Schuster, Stephen J.
    Romanov, Vadim V.
    Rusch, Elisha S.
    Signorovitch, James
    Ericson, Solveig G.
    Maloney, David G.
    Locke, Frederick L.
    BLOOD, 2018, 132
12345